NEW YORK–(BUSINESS WIRE)–Hyprevention Inc. (“Hyprevention”), a medtech company, announced today that it incorporated in Delaware, becoming the new parent company of the group previously established in France in 2010. Hyprevention develops and markets the Strutplasty® Technology. The Strutplasty® Technology is 510K cleared, under the trade name V-Strut© Transpedicular Vertebral Implant. The technology reinforces weakened bone due to osteoporosis or cancer in the vertebral body. Initial U.S. commercialization has demonstrated strong clinical outcomes and growth.
Cecile Vienney, CEO, and founder of Hyprevention stated “Establishing Hyprevention as a U.S. company will allow us to be laser focused on growing the U.S. sales team and bringing a next generation product to physicians that treat patients with vertebral fractures. I founded Hyprevention to solve problems in the current standard of care addressing vertebral fractures.” In addition to establishing Hyprevention as a U.S. based product, the company appointed Kathryn Larson to the Board of Directors. “Kathryn brings a wealth of commercial knowledge and experience to Hyprevention, including her most recent success with Vertiflex (acquired by Boston Scientific Inc). Kathryn will help further the U.S. launch of V-Strut and provide direction to our commercial teams.”
Hyprevention investor Yellowstone Holdings led the additional funding in early 2024 to support the company in its U.S. transition.
About the Hyprevention Inc.
Hyprevention is focused on the development and marketing of the V-Strut© Transpedicular Implant. It is intended for use in the treatment of thoraco-lumbar vertebral fractures. The technology combining PEEK Polymer implant along with bone cement repairs, distributes, and absorbs stresses of the vertebra to treat fractures, including pedicle fractures, while reducing adjacent level fractures.
Whereas vertebral body fractures are well known, pedicle involvement is common in osteoporosis (64%) and malignant (84%) fractures, V-Strut© is the only 510K cleared products on the market address this clinical need.
Contacts
Cecile Vienney, CEO
usa@hyprevention.com
(001) 722 228 3218
www.hyprevention.com